Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Moldova

Moldova

The Neoplasm Treatment market in Moldova is expected to witness a significant surge in revenue, reaching a projected value of US$32.01m by 2024.
This growth is further anticipated to continue at a steady pace, with an annual growth rate (CAGR 2024-2029) of 2.54%.
As a result, the market volume is estimated to reach US$36.29m by 2029.
In a global context, it is noteworthy that United States will dominate the Neoplasm Treatment market, generating the highest revenue of US$90.56bn in 2024.
Moldova is witnessing a growing trend in the adoption of advanced neoplasm treatment techniques, improving patient outcomes and fostering innovation in the healthcare sector.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.